Melanoma

  1. A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma
    The purpose of the study is to compare relatlimab and nivolumab combination therapy to nivolumab therapy in research subjects with previously untreated melanoma with metastases or melanoma that is unsuited for surgery.
    Primary researcher: Micaela Hernberg
 

 Contact Information

 
haluantutkimuspotilaaksi@hus.fi
tel. +358 50 427 0680